Generon (Shanghai) Corporation Ltd. Initiates a Phase I Clinical Study for F-652 in Australia
Published: Sep 06, 2012
SHANGHAI--(BUSINESS WIRE)--Generon (Shanghai) Corporation Ltd. today announced the initiation of a Phase I clinical trial for F-652 in Australia. F-652 is a recombinant protein containing a human interleukin-22 (IL-22) dimer. The current Phase I study is to evaluate the safety and pharmacokinetics (PK) profile and identify biomarkers for F-652 in healthy volunteers.